rHDL administration increases reverse cholesterol transport in mice, but is not additive on top of ezetimibe or cholestyramine treatment

Atherosclerosis

Volumn 229, Issue 1, 2013, Pages 94-101

  Maugeais, Cyrille ^a   Annema, Wijtske ^b,c   Blum, Denise ^a   Mary, Jean Luc ^a   Tietge, Uwe J F ^b,c  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

Author keywords

Cholesterol; CVD; HDL; LDL; NPC1L1; RCT; Reverse cholesterol transport; Sterol excretion; VLDL

Indexed keywords

COLESTYRAMINE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN; RECONSTITUTED HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FECES; FOAM CELL; IN VIVO STUDY; INTESTINE ABSORPTION; MACROPHAGE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; REVERSE CHOLESTEROL TRANSPORT; SINGLE DRUG DOSE; STEROL EXCRETION; WILD TYPE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN A-I; AZETIDINES; BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CHOLESTEROL, HDL; CHOLESTYRAMINE RESIN; DRUG SYNERGISM; FECES; INTESTINAL ABSORPTION; LIVER; MACROPHAGES; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; STEROLS; TRIGLYCERIDES;

EID: 84879413728     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.04.009     Document Type: Article

References (32)

1. Assmann G., Gotto A.M. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004, 109:III8-14.
2. Linsel-Nitschke P., Tall A.R. HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005, 4:193-205.
3. Rader D.J., Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008, 451:904-913.
4. Brewer H.B. Clinical review: the evolving role of HDL in the treatment of high-risk patients with cardiovascular disease. JClin Endocrinol Metab 2011, 96:1246-1257.
5. Tangirala R.K., Tsukamoto K., Chun S.H., et al. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999, 100:1816-1822.
6. Annema W., Tietge U.J. Role of hepatic lipase and endothelial lipase in high-density lipoprotein-mediated reverse cholesterol transport. Curr Atheroscler Rep 2011, 13:257-265.
7. Nijstad N., Gautier T., Briand F., et al. Biliary sterol secretion is required for functional invivo reverse cholesterol transport in mice. Gastroenterology 2011, 140:1043-1051.
8. Annema W., Tietge U.J. Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. Nutr Metab (Lond) 2012, 9:25.
9. Zhang Y., Zanotti I., Reilly M.P., et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces invivo. Circulation 2003, 108:661-663.
10. Tardif J.C. Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?. JClin Lipidol 2010, 4:399-404.
11. Shah P.K. Apolipoprotein A-I/HDL infusion therapy for plaque stabilization-regression: a novel therapeutic approach. Curr Pharm Des 2007, 13:1031-1038.
12. Matz C.E., Jonas A. Micellar complexes of human apolipoprotein A-I with phosphatidylcholines and cholesterol prepared from cholate-lipid dispersions. JBiol Chem 1982, 257:4535-4540.
13. Tietge U.J., Pratico D., Ding T., et al. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. JLipid Res 2005, 46:1604-1614.
14. Annema W., Nijstad N., Tolle M., et al. Myeloperoxidase and serum amyloid A contribute to impaired invivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). JLipid Res 2010, 51:743-754.
15. de Boer J.F., Annema W., Schreurs M., et al. Type I diabetes mellitus decreases invivo macrophage-to-feces reverse cholesterol transport despite increased biliary sterol secretion in mice. JLipid Res 2012, 53:348-357.
16. Tietge U.J.F., Maugeais C., Cain W., et al. Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. JBiol Chem 2000, 275:10077-10084.
17. Nissen S.E., Tsunoda T., Tuzcu E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAm Med Assoc 2003, 290:2292-2300.
18. Tardif J.C., Gregoire J., L'Allier P.L., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007, 297:1675-1682.
19. Woollard K.J., Geissmann F. Monocytes in atherosclerosis: subsets and functions. Nat Rev Cardiol 2010, 7:77-86.
20. Feig J.E., Rong J.X., Shamir R., et al. HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A 2011, 108:7166-7171.
21. Trogan E., Feig J.E., Dogan S., et al. Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A 2006, 103:3781-3786.
22. Davis H.R., Compton D.S., Hoos L., et al. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001, 21:2032-2038.
23. Umemoto T., Subramanian S., Ding Y., et al. Inhibition of intestinal cholesterol absorption decreases atherosclerosis but not adipose tissue inflammation. JLipid Res 2012, 53:2380-2389.
24. Sehayek E., Hazen S.L. Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages. Arterioscler Thromb Vasc Biol 2008, 28:1296-1297.
25. Briand F., Naik S.U., Fuki I., et al. Both the peroxisome proliferator-activated receptor delta agonist, GW0742, and ezetimibe promote reverse cholesterol transport in mice by reducing intestinal reabsorption of HDL-derived cholesterol. Clin Transl Sci 2009, 2:127-133.
26. Bays H.E., Goldberg R.B. The 'forgotten' bile acid sequestrants: is now a good time to remember?. Am J Ther 2007, 14:567-580.
27. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251:351-364.
28. Kritchevsky D., Kim H.K., Tepper S.A. Effect of colestipol (U-26,597A) on experimental atherosclerosis in rabbits. Proc Soc Exp Biol Med 1973, 142:185-188.
29. Thomson A.B., Schoeller C., Keelan M., et al. Lipid absorption: passing through the unstirred layers, brush-border membrane, and beyond. Can J Physiol Pharmacol 1993, 71:531-555.
30. Shah P.K., Yano J., Reyes O., et al. High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 2001, 103:3047-3050.
31. Wang Y., Berbee J.F., Stroes E.S., et al. CETP expression reverses the reconstituted HDL-induced increase in VLDL. JLipid Res 2011, 52:1533-1541.
32. Chen Z., O'Neill E.A., Meurer R.D., et al. Reconstituted HDL elicits marked changes in plasma lipids following single-dose injection in C57Bl/6 mice. JCardiovasc Pharmacol Ther 2012, 17:315-323.